Cleveland Clinic Taussig Cancer Institute
Taussig Cancer Institute is the hub for Cleveland Clinic Cancer Center.
Nivo +/- Ipi, or Pembro Recommended as 2nd Line for mCRC, Trials on IO vs. Chemo or + Chemo Are Underway for MSI-High mCRC and Adjuvant, Ragorafenib + Nivo Resulted in 36% RR in MSS Disease
Login to view comments.
Click here to Login